Shots:
- Alkem Laboratories has launched Pertuza 420mg/14mL, a Perjeta biosimilar, across India for treating HER2-positive breast cancer
- In a P-III trial, Pertuza showed equivalent efficacy, safety, and immunogenicity to the reference product
- Pertuzumab is a HER2/neu receptor antagonist that was approved for HER2-positive breast cancer
Ref: Alkem Laboratories | Image: Alkem Laboratories | Press Release
Related News:- CuraTeQ Biologics Reports Positive P-III study results for Denosumab biosimilar for postmenopausal osteoporosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
